Skip to main content

Table 1 Socio-demographic and tumour characteristics associated with use of adjuvant chemotherapya

From: A cohort study of ethnic differences in use of adjuvant chemotherapy and radiation therapy for breast cancer in New Zealand

  Use of chemotherapy
Characteristic Total population (N = 1212) Total chemotherapy (N = 1212) NZ European (N = 924) Māori (N = 218)
  n (%) n (%)b p n (%)b n (%)b
Overall 1212 (100) 836 (69.0)   635 (68.7) 149 (68.3)
Age (yrs.)    <0.001   
  < 40 100 (8.3) 90 (90.0)   58 (89.2) 18 (90.0)
 40-49 338 (27.9) 276 (81.7)   200 (81.3) 56 (81.2)
 50-59 434 (35.8) 309 (71.2)   245 (72.5) 53 (68.8)
 60-69 340 (28.1) 161 (47.4)   132 (48.0) 22 (42.3)
Deprivation    0.402   
 Dep 1-2 139 (11.5) 100 (71.9)   88 (71.5) 8 (80.0)
 Dep 3-4 126 (10.4) 89 (70.6)   72 (70.6) 12 (75.0)
 Dep 5-6 313 (25.8) 216 (69.0)   174 (67.7) 29 (70.7)
 Dep 7-8 315 (26.0) 213 (67.6)   160 (67.8) 39 (61.9)
 Dep 9-10 319 (26.3) 218 (68.3)   141 (68.4) 61 (69.3)
Surgical hospital type   0.002   
 Private 406 (33.5) 303 (74.6)   271 (74.0) 21 (80.8)
 Public 806 (66.5) 533 (66.1)   364 (65.2) 128 (66.7)
Diagnostic type    0.033   
 Screen detected 407 (33.6) 235 (57.7)   195 (57.9) 30 (57.7)
 Non-screen detected 805 (66.4) 601 (74.7)   440 (75.0) 119 (71.7)
Charlson score    <0.001   
 0 1056 (87.1) 754 (71.4)   582 (70.5) 124 (71.7)
 1+ 156 (12.9) 82 (52.6)   53 (53.5) 25 (55.6)
Diagnosis year    0.003   
 1999-2002 269 (22.2) 201 (74.7)   160 (73.7) 31 (79.5)
 2003-2006 374 (30.9) 267 (71.4)   216 (72.5) 38 (66.7)
 2007-2009 292 (24.1) 183 (62.7)   128 (60.7) 39 (65.0)
 2010-2012 277 (22.9) 185 (66.8)   131 (66.2) 41 (66.1)
Grade    <0.001   
 Grade I 168 (13.9) 70 (41.7)   62 (43.4) 6 (33.3)
 Grade II 617 (50.9) 409 (66.3)   305 (66.0) 83 (66.9)
 Grade III 395 (32.6) 340 (86.1)   254 (85.8) 57 (83.8)
 Missing 32 (2.6) 17 (53.1)   14 (60.9) 3 (37.5)
ER/PR status    <0.001   
 ER &/or PR + 926 (76.4) 598 (64.6)   457 (64.3) 103 (63.6)
 ER & PR - 276 (22.8) 233 (84.4)   173 (84.4) 46 (83.6)
 Missing 10 (0.8) 5 (50.0)   5 (62.5) 0
T stage    <0.001   
 T1 368 (30.4) 234 (63.6)   196 (62,6) 29 (69.0)
 T2 692 (57.1) 484 (69.9)   364 (71.4) 83 (62.4)
 T3 83 (6.8) 64 (77.1)   40 (74.1) 19 (82.6)
 T4 62 (5.1) 50 (80.6)   31 (77.5) 18 (90.0)
 Missing 7 (0.6) 4 (55.6)   4 (55.6) 0
N stage    <0.001   
 0 406 (33.5) 223 (54.9)   165 (54.6) 37 (50.0)
 1 537 (44.3) 381 (70.9)   291 (70.0) 72 (74.2)
 2+ 269 (22.2) 232 (86.2)   179 (86.9) 40 (85.1)
LVI    <0.001   
 Negative 783 (64.6) 484 (61.8)   362 (61.0) 88 (62.0)
 Positive 429 (35.4) 352 (82.1)   273 (82.5) 61 (80.3)
HER-2    <0.001   
 Negative 658 (54.3) 414 (62.9)   314 (63.2) 79 (60.8)
 Equivocal 48 (4.0) 25 (52.1)   17 (48.6) 6 (66.7)
 Positive 219 (18.1) 188 (85.8)   134 (86.5) 37 (80.4)
 Missing 287 (23.7) 209 (72.8)   170 (71.7) 27 (81.8)
  1. aOnly ER and PR negative cancers ≥10mm and ER and/or PR positive cancers ≥20mm in women <70 years are included
  2. bProportion of women who had received chemotherapy in each category